# Sermorelin Dosage in the Research Literature: Studied Doses and Routes > Sermorelin dosage as studied in research: pediatric, aging, diagnostic, and pharmacokinetic regimens, with routes and handling. Studied-at-X framing, fully cited. The doses, routes, timing, and handling that appear in the published studies — read as instrument readings, not as instructions. ## Before the details This page reports the sermorelin dosage figures that appear in the published research — the amounts, the timing, and the delivery routes that investigators used. It is descriptive, not prescriptive: every number below is written as "studied at X in [population]" and none of it is a recommendation to self-administer. Research-grade sermorelin is supplied for laboratory research, not as a finished medicine. With that framing fixed, here is what the dose-response and pharmacokinetic record actually contains. ## Sermorelin dosage in the research literature The studied doses span four research contexts, and they differ by purpose. In the pediatric growth-hormone-deficiency efficacy study, GHRH(1-29) was given at 30 mcg/kg/day subcutaneously at bedtime [2]. In aging research in older men, 0.5 mg and 1 mg were administered subcutaneously twice daily for 14 days [6]. For diagnostic GH stimulation, a single intravenous bolus (commonly around 1 mcg/kg) was historically used to test pituitary GH reserve. And in the pharmacokinetic study, intravenous doses of 0.25-2 mcg/kg elicited GH release in healthy men [3]. These are research and historical-clinical regimens, reported to document the dose-response relationship — not a protocol for use. The pediatric efficacy dose and the aging-research dose were chosen for different endpoints (linear growth versus reversal of age-related GH/IGF-1 decline), which is why a single "sermorelin dose" does not exist in the literature; the dose is matched to the question being asked [2][6]. ## Reading the dose figures in context The studied doses are best understood as instrument readings tied to specific endpoints rather than as a ladder of escalating strength. The pediatric figure (30 mcg/kg/day subcutaneously at bedtime) was calibrated to drive linear growth in children whose own GH output was deficient, and it accelerated first-year height velocity without excessive IGF-1 generation [2]. The aging-research figures (0.5 mg and 1 mg twice daily for 14 days) were calibrated to a different question — whether a GHRH stimulus could restore the GH/IGF-1 levels that fall with age — and at the high dose those parameters reached values indistinguishable from young men [6]. The pharmacokinetic doses are different again: the 0.25-2 mcg/kg intravenous range in healthy men was used to map the dose-response curve for acute GH release, not to treat anything, and it showed GH release beginning at the very bottom of that range [3]. None of these is a target for personal use; together they show that the literature reports several doses because it asked several different research questions. Reported as "studied at X in [population]," each figure stays anchored to the study that measured it. ## Why is sermorelin studied with bedtime dosing? Endogenous GH is secreted in pulses concentrated during slow-wave sleep, so bedtime GHRH dosing aligns the stimulus with the body's natural nocturnal GH surge. Both the pediatric efficacy regimen and the elderly-men studies used bedtime or nightly subcutaneous administration for this reason [2][14]. The timing is mechanistic: a GHRH agonist given when the somatotrophs are primed to fire reinforces the existing rhythm rather than fighting it. This describes the studied schedule, not a personal dosing time. ## What route was sermorelin studied by? Subcutaneous injection is the primary route used in research; intravenous dosing was used in diagnostic and pharmacokinetic studies. A historical intranasal route was tested and showed only about 3-5% bioavailability, which is why systemic delivery relies on injection rather than nasal or mucosal absorption [3]. This consistent finding — that the peptide is poorly absorbed across mucosa — is also why oral, sublingual, and troche "sermorelin" formulations are widely criticized in research-user communities as ineffective: peptides are degraded in the gut and poorly absorbed across the oral mucosa. The route data describe how studies delivered the peptide, not a self-administration instruction. ## How is sermorelin stored and handled in research settings? Sermorelin is supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions degrade over time. Once reconstituted with sterile diluent, it is typically refrigerated, and compounded preparations are prepared under USP <797> sterile-compounding standards [1]. The handling logic follows directly from the chemistry: the peptide is stable dry and labile in solution, so it is kept dry until needed and cold once mixed. These are laboratory and compounding handling practices reported in the literature, not directions for personal use. ## Half-life and the dose-duration relationship Dosage cannot be read apart from clearance. Sermorelin's plasma half-life is approximately 10-12 minutes after intravenous administration, yet a single dose holds serum GH elevated for about three hours [3]. That brief-impulse-to-sustained-signal profile is why the native peptide is dosed for an acute pulse rather than continuous coverage, and why longer-acting analogs were engineered when sustained GHRH stimulation was the goal — the structure-activity story told on the [sermorelin vs CJC-1295](/vs-cjc-1295) page. The full pharmacokinetic detail lives on the [sermorelin mechanism of action](/mechanism-of-action) page. --- A near-monochrome instrument reading of the sermorelin record — the GHRH(1-29) pulse traced from receptor to IGF-1 and each figure logged to its study, the body-composition data attributed to tesamorelin where it belongs and the silence where the adult anti-aging evidence runs out left unfilled; no clinic behind the console and nothing here compounded, dosed, or sold.